$4.10
0.37% today
Nasdaq, Sep 09, 05:19 pm CET
ISIN
CA74319B5027
Symbol
PROF

Profound Medical Corp Stock News

Neutral
GlobeNewsWire
12 days ago
TORONTO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in the Lake Street Capital Markets “BIG9” Conference on September 11, 2025 in New Yor...
Negative
Seeking Alpha
22 days ago
I am initiating Profound Medical Corp. at a Sell rating with a fair value of $2.9 per share due to financial concerns. TULSA-PRO shows promise for BPH and localized prostate cancer, but long-term efficacy and sales growth remain uncertain. Heavy reliance on share issuance, high SBC relative to revenue, and ongoing negative cash flow raise significant balance sheet risks.
Neutral
Seeking Alpha
26 days ago
Profound Medical Corp. (NASDAQ:PROF ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Arun Swarup Menawat - Chairman of the Board & CEO Mathieu Burtnyk - President Rashed Dewan - Chief Financial Officer Stephen Kilmer - Corporate Participant Investor Relations - Corporate Participant Thomas Tamberrino - Chief Commercial Officer Conference Call Participants Benja...
Neutral
GlobeNewsWire
26 days ago
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the second quarter ended June 30, 2025. Unless specified otherwise, all amo...
Neutral
GlobeNewsWire
about 2 months ago
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025.
Neutral
GlobeNewsWire
4 months ago
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the M...
Neutral
Seeking Alpha
4 months ago
Profound Medical Corporation (NASDAQ:PROF ) Q1 2025 - Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Stephen Kilmer - Head IR Rashed Dewan - CFO Dr. Mathieu Burtnyk - COO Tom Tamberrino - Chief Commercial Officer Arun Menawat - CEO Conference Call Participants Ben Haynor - Lake Street Capital Markets John McAuley - Stifel Michael Freeman - Raymond James Scott McAuley - Par...
Neutral
GlobeNewsWire
4 months ago
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2025 Bloom Burton & Co. Healthcare Investor C...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today